Avelox 400 mg/250 ml solution for infusion
Last Updated on eMC 17-May-2017 View document | Bayer plc Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 17-May-2017 and displayed until Current
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 25-Aug-2015 and displayed until 17-May-2017
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 01-Jul-2015 and displayed until 25-Aug-2015
Reasons for adding or updating:
- Change to section 4 - how to report a side effect
- Change to section 5 - how to store
- Change to section 6 - what the product contains
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 23-Nov-2012 and displayed until 01-Jul-2015
Reasons for adding or updating:
- Change to date of revision
Updated on 16-Oct-2012 and displayed until 23-Nov-2012
Reasons for adding or updating:
- Updates to formatting
Updated on 11-Oct-2012 and displayed until 16-Oct-2012
Reasons for adding or updating:
- Removal of Black Triangle
Updated on 04-Jan-2012 and displayed until 11-Oct-2012
Reasons for adding or updating:
- Change to date of revision
Updated on 08-Aug-2011 and displayed until 04-Jan-2012
Reasons for adding or updating:
- Change to storage instructions
Updated on 26-Oct-2010 and displayed until 08-Aug-2011
Reasons for adding or updating:
- Change to warnings or special precautions for use
- Change to side-effects
Updated on 10-Mar-2010 and displayed until 26-Oct-2010
Reasons for adding or updating:
- New PIL for new product
Bayer plc
Bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA
+44 (0)1635 563 393
+44 (0)1635 563 000
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue